- Home
- CHRS vs LCNB Comparison
CHRS vs LCNB Comparison
Compare CHRS & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- LCNB
- Stock Information
- Founded
- CHRS 2010
- LCNB 1877
- Country
- CHRS United States
- LCNB United States
- Employees
- CHRS N/A
- LCNB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- LCNB Major Banks
- Sector
- CHRS Health Care
- LCNB Finance
- Exchange
- CHRS Nasdaq
- LCNB Nasdaq
- Market Cap
- CHRS 185.5M
- LCNB 212.3M
- IPO Year
- CHRS 2014
- LCNB N/A
- Fundamental
- Price
- CHRS $1.52
- LCNB $15.83
- Analyst Decision
- CHRS Strong Buy
- LCNB
- Analyst Count
- CHRS 4
- LCNB 0
- Target Price
- CHRS $5.38
- LCNB N/A
- AVG Volume (30 Days)
- CHRS 10.1M
- LCNB 26.1K
- Earning Date
- CHRS 11-06-2024
- LCNB 01-29-2025
- Dividend Yield
- CHRS N/A
- LCNB 5.77%
- EPS Growth
- CHRS N/A
- LCNB N/A
- EPS
- CHRS N/A
- LCNB 0.52
- Revenue
- CHRS $304,340,000.00
- LCNB $74,686,000.00
- Revenue This Year
- CHRS $1.64
- LCNB N/A
- Revenue Next Year
- CHRS $16.98
- LCNB $15.49
- P/E Ratio
- CHRS N/A
- LCNB $29.28
- Revenue Growth
- CHRS 44.19
- LCNB 3.03
- 52 Week Low
- CHRS $0.66
- LCNB $12.42
- 52 Week High
- CHRS $3.70
- LCNB $17.92
- Technical
- Relative Strength Index (RSI)
- CHRS 52.47
- LCNB 36.98
- Support Level
- CHRS $1.45
- LCNB $15.51
- Resistance Level
- CHRS $1.85
- LCNB $16.84
- Average True Range (ATR)
- CHRS 0.23
- LCNB 0.55
- MACD
- CHRS -0.03
- LCNB -0.21
- Stochastic Oscillator
- CHRS 3.88
- LCNB 22.75
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.